Galapagos achieves milestones in two strategic alliances
BioFocus division also extends agreement with Chiesi Farmaceutici
Belgian biotechnology firm Galapagos has achieved milestones totalling €2.5m from its alliances with Janssen Pharmaceutica and GlaxoSmithKline (GSK).
Janssen Pharmaceutica has paid Galapagos €1.5m in its rheumatoid arthritis agreement, taking the total earned by Galapagos to date from Janssen to more than €24m.
In Galapagos' alliance with GSK in the area of infectious diseases, the firm has received a €1m milestone payment. Since this alliance was formed in 2007, Galapagos has received a total of €6m from GSK.
‘Galapagos continues to make progress across its strategic alliances, showing that our alliance model delivers strong growth in r&d revenues,’ said Onno van de Stolpe, ceo of Galapagos.
In a separate announcement, Galapagos’ BioFocus service division has expanded its collaboration with Chiesi Farmaceutici, a privately held Italian pharmaceutical company. The total value of the collaboration has now reached €2.5m.
BioFocus and Chiesi began their collaboration in December 2009 and recently extended it for one year. Under the extension, BioFocus will provide medicinal chemistry and biology services, with an additional option for ADME services, for an undisclosed Chiesi therapeutic programme.
